IGEA Pharma Past Earnings Performance
Past criteria checks 0/6
IGEA Pharma's earnings have been declining at an average annual rate of -57.7%, while the Medical Equipment industry saw earnings growing at 4.2% annually. Revenues have been declining at an average rate of 42.6% per year.
Key information
-57.7%
Earnings growth rate
37.4%
EPS growth rate
| Medical Equipment Industry Growth | 4.3% |
| Revenue growth rate | -42.6% |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How IGEA Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 0 | -12 | 11 | 0 |
| 31 Mar 23 | 0 | -12 | 11 | 0 |
| 31 Dec 22 | 0 | -12 | 11 | 0 |
| 30 Sep 22 | 0 | -6 | 6 | 0 |
| 30 Jun 22 | 0 | -1 | 1 | 0 |
| 31 Mar 22 | 0 | -1 | 1 | 0 |
| 31 Dec 21 | 0 | -1 | 1 | 0 |
| 30 Sep 21 | 0 | -1 | 1 | 0 |
| 30 Jun 21 | 0 | -1 | 1 | 0 |
| 31 Mar 21 | 0 | -1 | 1 | 0 |
| 31 Dec 20 | 0 | -1 | 1 | 0 |
| 30 Sep 20 | 0 | -1 | 1 | 0 |
| 30 Jun 20 | 0 | -1 | 1 | 0 |
| 31 Mar 20 | 0 | -2 | 1 | 0 |
| 31 Dec 19 | 0 | -2 | 1 | 0 |
| 30 Sep 19 | 0 | -2 | 1 | 0 |
| 30 Jun 19 | 0 | -2 | 2 | 0 |
| 31 Mar 19 | 0 | -2 | 1 | 0 |
| 31 Dec 18 | 0 | -1 | 1 | 0 |
| 31 Dec 17 | 0 | 0 | 0 | 0 |
Quality Earnings: 3B5 is currently unprofitable.
Growing Profit Margin: 3B5 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 3B5 is unprofitable, and losses have increased over the past 5 years at a rate of 57.7% per year.
Accelerating Growth: Unable to compare 3B5's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 3B5 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-1.2%).
Return on Equity
High ROE: 3B5's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.